Turn the “golden hour” into the “golden day” – Our research data suggest that the PEG-20k IV solution could increase the time that a patient can safely stay in the low volume state after a massive hemorrhage 10 times longer than with conventional IV solutions. And research efforts have shown impressive potential for other indications such as sepsis, cardiac arrest, and TBI. We are dedicated to taking PEG-20k through clinical trials and the regulatory approval process so it can be used to save lives!
World-Class Research Team: The research team at Virginia Commonwealth University School of Medicine includes Dr. Martin Mangino and Dr. Loren Liebrecht. Dr. Mangino has over 35 years of academic experience in the area of ischemia, reperfusion, shock, and critical illness research.
Highly Experienced Management Team: The entrepreneurial team include company CEO, Gerard Eldering, executive Gordon Van Dusen and FDA consultants Paul Manberg and Paul Dryden
Perfusion Medical has licensed PEG-20k from Virginia Commonwealth University and is planning initial clinical trials at the VCU School of Medicine
Perfusion Medical has brought together a world class team of researchers, life science entrepreneurs, advisors and supporting organizations.